Significance of rest technetium-99m sestamibi imaging for the prediction of improvement of left ventricular dysfunction after q wave myocardial infarction: importance of infarct location adjusted thresholds  by Schneider, Christian A et al.
Significance of Rest Technetium-99m Sestamibi Imaging for the
Prediction of Improvement of Left Ventricular Dysfunction After
Q Wave Myocardial Infarction: Importance of Infarct Location
Adjusted Thresholds
CHRISTIAN A. SCHNEIDER, MD, EBERHARD VOTH, MD,* SYBILLE GAWLICH, MD,
FRANK M. BAER, MD, MICHAEL HORST, MD,† HARALD SCHICHA, MD,*
ERLAND ERDMANN, MD, FACC, UDO SECHTEM, MD, FACC‡
Ko¨ln and Stuttgart, Germany
Objective. The value of rest technetium-99m (Tc-99m) sesta-
mibi scintigraphy under oral nitrate medication to predict myo-
cardial viability was examined in patients with chronic infarcts.
Background. The value of rest Tc-99m sestamibi to predict
viability in infarct regions has not been fully established because
significant underestimation of viability, especially in the inferior
myocardial wall, has been reported.
Methods. Forty patients with Q wave myocardial infarction
underwent Tc-99m sestamibi single-photon emission computed
tomography under nitrate medication before revascularization of
the infarct-related artery. Wall motion was quantified from paired
angiograms before and 4 months after revascularization. Tracer
uptake was quantified in the central infarct region identified on
the angiogram.
Results. The average Tc-99m sestamibi uptake in the central
infarct region of patients with anterior infarcts and improvement
of left ventricular function was significantly higher (68 6 12%,
mean 6 SD) than in patients without improvement of function
(40 6 14%, p < 0.02). The average Tc-99m sestamibi uptake in the
central infarct region of patients with improvement of function
and inferior infarcts was significantly lower (43 6 7%) than in
patients with anterior infarcts (68 6 12%, p < 0.003), but was
significantly higher than in patients with inferior infarction and
no improvement of function (31 6 7%, p < 0.02). Using an infarct
location adjusted optimal threshold (50% for anterior infarcts,
35% for inferior infarcts), Tc-99m sestamibi had a positive
predictive value of 90% and a negative predictive value of 91% for
improvement of left ventricular function.
Conclusion. Quantitative rest Tc-99m sestamibi scintigraphy
after oral nitrates reliably predicts improvement of left ventricu-
lar function after revascularization if infarct location adjusted
thresholds are used.
(J Am Coll Cardiol 1998;32:648–54)
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Scintigraphic techniques are widely used for the reliable de-
tection of residual viability in infarct regions. Among the
tracers used, 18F-fluorodeoxyglucose (FDG) (1) and thallium-
201 (Tl-201) (2) are the most common. In addition,
technetium-99m (Tc-99m) sestamibi has been used to detect
residual viability in the infarct regions (3). However, the ability
of Tc-99m sestamibi single-photon emission computed tomog-
raphy (SPECT) to detect viable myocardium in the infarct
region and to predict functional improvement after myocardial
infarction has been controversially discussed because in some
studies Tc-99m sestamibi SPECT underestimated myocardial
viability identified by FDG positron emission tomography
(PET) or Tl-201 SPECT (4–6). These findings contrast to
recent reports showing good agreement of Tl-201 and Tc-99m
sestamibi in the detection of residual viability (7,8) and the
prediction of functional improvement (7,9,10). These discrep-
ancies may be explained in part by differences of the imaging
protocol and the analysis of the data: late imaging (11),
imaging after nitrate administration (12,13) or the quantitative
analysis of Tc-99m sestamibi uptake (7,8,11) can improve the
diagnostic accuracy of Tc-99m sestamibi SPECT to detect
residual viability.
On the basis of these findings we hypothesized that Tc-99m
sestamibi SPECT after oral nitrate with quantitative analysis
would have similar accuracy as FDG PET in detecting viable
myocardium in the infarct region and predicting improvement
of left ventricular function. We further hypothesized that the
average Tc-99m sestamibi uptake would depend on the infarct
location and would be significantly lower in inferior infarct
regions than in anterior infarct regions due to attenuation
effects. Accordingly, we analyzed the predictive value of Tc-
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99m sestamibi SPECT not only in the total group of patients
with myocardial infarction and successful revascularization but
also in subgroups according to infarct location (inferior vs.
anterior infarcts).
Methods
Study patients. Forty patients with Q wave myocardial
infarction and angiographically documented coronary artery
disease (at least one infarct-related major coronary vessel with
.75% diameter stenosis) and regional severe hypokinesia,
akinesia or dyskinesia by visual analysis of left ventricular
angiograms were prospectively studied. Infarct had occurred in
all patients .3 months before the first scintigraphic study.
Independently of the findings of the scintigraphic studies, all
patients underwent revascularization of the infarct-related
coronary artery between November 1994 and December 1996.
Four months after revascularization all patients underwent
repeat angiography and ventriculography.
An infarct was defined as anterior if the electrocardiogram
(ECG) showed pathological Q waves $30 ms in at least three
of the anterior infarct leads (I, aVL, V1–4) and a severe wall
motion abnormality in at least one of the anterior segments of
the right anterior oblique (RAO) angiogram (anterobasal,
anterolateral or apical); an infarct was defined as inferior if the
ECG showed pathologic Q waves in at least two inferior leads
(II, III, aVF, V6) and a wall motion abnormality in at least one
of the inferior segments of the RAO angiogram (posterobasal
or diaphragmatic).
For detection of myocardial viability all patients underwent
FDG PET and Tc-99m sestamibi SPECT on 2 separate days.
The revascularization procedure was performed within 5 days
after completion of the scintigraphic studies. No cardiac event
(myocardial infarction, unstable angina) occurred in any pa-
tient between the scintigraphic studies and angiography nor
between baseline and control angiography 4 months later. The
study was approved by the Hospital Human Rights Committee
(Institutional Review Board) and informed consent was ob-
tained from every patient.
Of the 40 patients initially included in the study, 9 were
excluded from analysis of the relation between Tc-99m sesta-
mibi uptake and improvement of function because of signifi-
cant restenosis (.75% diameter reduction) of the dilated
artery (n 5 6) or severe stenosis or occlusion of the bypass
graft (n 5 3) as persisting ischemia could have precluded an
improvement of function, and inclusion of patients with resten-
osis would have led to false calculation of the positive and
negative predictive values of Tc-99m sestamibi SPECT. Thus,
the Tc-99m sestamibi data are analyzed in two ways: 1) the
relation of viability as defined by FDG PET and average
Tc-99m sestamibi uptake was analyzed (40 patients); 2) the
relation of viability as defined by improvement of left ventric-
ular function after successful revascularization and Tc-99m
sestamibi uptake was evaluated (31 patients).
Angiography and ventriculography. Selective coronary an-
giography was performed by the Judkins technique and arter-
ies were viewed in multiple projections. Coronary artery
narrowing was measured in the projection showing the most
severe stenosis using electronic calipers. A diameter reduction
of $50% was considered significant.
Biplane left ventriculography was performed in the right
(RAO) and left anterior oblique position. Regional left ven-
tricular wall motion of the infarct region was quantified and
expressed as standard deviation (SD) of a normal population
per chord using the centerline method (14). Wall motion
analysis was performed using the RAO projection because
hypokinesia is more accurately detected in this projection for
anterior and inferior infarction (14). In addition, the analysis in
the RAO projection avoids inclusion of septal segments with
wall motion abnormalities caused by coronary artery bypass
graft surgery. Two patients had a hypoplastic right coronary
artery and a dominant circumflex coronary artery as the infarct
artery leading to akinesia of the inferior wall. The ventriculo-
grams of these patients were also analyzed in the right anterior
oblique projection. Wall motion in the central infarct region
was analyzed by averaging the motion of chords lying in the
most abnormally contracting 50% of the infarct territory and is
expressed as mean SD/chord. An increase in SD of the central
infarct region at control angiography by .0.8 SD in patients
with anterior infarcts and .0.6 SD in patients with inferior
infarcts was defined as significant improvement of left ventric-
ular wall motion indicative of recovery of viable myocardium
(14). Global left ventricular ejection fraction was calculated
from end-diastolic and end-systolic contours using the area
length method (15).
Scintigraphic studies. Tc-99m sestamibi SPECT. All pa-
tients received their individually tolerated maximal oral doses
of long-acting nitrates (mean doses 85 6 35 mg of dinitrates)
at 8:00 AM on the day of SPECT examination. Two hours later,
740 MBq (20 mCi) of Tc-99m sestamibi (Cardiolite, DuPont,
Bad Homburg, Germany) were injected. One hour after this
injection all patients received a standard meal to improve
Tc-99m sestamibi clearance from the hepato-biliary tract.
SPECT was finally started 2 h after Tc-99m sestamibi injection.
Tc-99m sestamibi imaging was performed with a triple-head
gamma camera (Prism 3000; Picker International GmbH,
Cleveland, OH and Munich, Germany) equipped with high
resolution collimators, as previously described (16). In a step-
and shoot-mode, 120 planar images (128 3 128-pixel matrix),
each with an acquisition time of 30 s, were acquired over a 360°
arc. Transaxial tomograms of 2 mm thick sections (1 pixel)
Abbreviations and Acronyms
FDG 5 18F-fluorodeoxyglucose
PET 5 positron emission tomography
RAO 5 right anterior oblique
SD 5 standard deviation
SPECT 5 single-photon emission computed tomography
Tl-201 5 thallium-201
Tc-99m 5 technetium-99m
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were reconstructed by means of filtered backprojection (But-
terworth filter, order 6, cut off frequency 0.35 cycles/pixel). The
images were then transferred to a SUN workstation for further
analysis.
FDG PET. 18F-fluorodeoxyglucose PET was performed
using a whole body scanner (Siemens CTI ECAT Exact 921,
Erlangen, Germany). To improve myocardial glucose uptake,
each patient received a solution of 50 g of glucose 1 h before
the administration of FDG. Images were corrected for atten-
uation by using coefficients measured by a transmission scan of
30-min duration. Emission scans (6 3 5 min) were started
30 min after injection of 370 MBq of FDG, as previously
described (17).
Image analysis. Positron emission tomography and SPECT
images were analyzed using computer generated polar maps on
a SUN SPARC 20 workstation by a single observer unaware of
the functional outcome of the patient after revascularization.
The FDG images were normalized to the region with maximal
Tc-99m sestamibi uptake (normalized, maximum FDG up-
take). The average FDG and Tc-99m sestamibi uptake in the
central infarct region were then quantified in the midventricu-
lar, sagittal long axis slice, showing the largest cavity, using a
continuous color scale and matching the scintigraphic images
and the right anterior oblique angiogram as its centerline
analysis side by side (Fig. 1). Slice thickness of the sagittal
image was 2.5 cm for both the Tc-99m sestamibi and FDG PET
images.
We have previously shown that a threshold of 50% of
maximal FDG uptake discriminates myocardium with larger
amounts of viable myocardium sufficient to improve left ven-
tricular function after revascularization (viable) with high
sensitivity and specificity from myocardium with only minimal
residual viability insufficient to improve left ventricular func-
tion (nonviable) (17). Accordingly, the central infarct region
with an average FDG uptake of ,50% of maximal, normalized
FDG uptake was defined as nonviable; the central infarct
region with an average uptake of $50% of maximal, normal-
ized FDG uptake was defined as viable.
Statistics. All data are presented as mean 6 SD. Differ-
ences between the mean values were compared using the
Wilcoxon signed rank test or the Mann-Whitney U-test, where
appropriate. The null hypothesis was rejected at the 95%
confidence level considering a p value ,0.05 as significant.
Figure 1. (A) The RAO angiogram as the centerline analysis of a
representative patient with an inferior myocardial infarction and
severe hypokinesia and akinesia of the diaphragmatic and posterobasal
wall. Wall motion abnormality of the central infarct region was
23.2 SD (arrows). This region was used as the reference region for the
quantitative analysis of Tc-99m sestamibi and FDG uptake. The global
ejection fraction was 52%. (B) Midventricular sagittal long axis slice
for the analysis of Tc-99m sestamibi uptake. The average Tc-99m
sestamibi uptake was 50%. (C) Midventricular sagittal long axis slice
for the analysis of FDG uptake. The average FDG uptake was 68%.
(D) RAO centerline analysis 4 months after angiographically proven
successful revascularization. Wall motion abnormality of the central
infarct region has improved by 1.76 SD to 21.44 SD. The global
ejection fraction at this control angiography was 62%.
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Positive and negative predictive values and the diagnostic
accuracy of scintigraphic values were calculated using standard
formulas.
Results
Patient characteristics. A total of 40 patients underwent
PET, Tc-99m sestamibi SPECT and revascularization of the
infarct-related vessel (Table 1). Indication for revasculariza-
tion included typical angina pectoris or a pathologic stress test
in 36 patients and severe dyspnoe judged as of cardiac origin in
4 patients.
The mean ejection fraction at baseline was 54 6 12%; 16
patients had single vessel disease, 6 patients had two vessel
disease and 18 patients had three vessel disease. The infarct-
related vessel was totally occluded in 11 patients, whereas a
subtotally occluded infarct-related vessel was found in 20
patients. The remaining nine patients had .75% diameter
stenosis of the infarct-related vessel. Figure 1 shows a repre-
sentative example of a patient with an inferior infarct and
improvement of wall motion abnormality 4 months after
successful revascularization.
Average Tc-99m sestamibi uptake in regions defined as viable
and nonviable by PET. The average Tc-99m sestamibi uptake
in the central infarct regions of patients defined as viable by
FDG PET was 51 6 14% (n 5 23) in the total group and was
significantly higher than in patients with an FDG uptake
,50% (33 6 7%; n 5 17; p , 0.007).
The average Tc-99m sestamibi uptake in the central infarct
region of patients with anterior infarcts scored as viable by
FDG PET was significantly higher (65 6 14%; n 5 8) than in
patients with anterior infarcts scored as nonviable by FDG
PET (33 6 9%, n 5 10; p , 0.0003; Fig. 2).
The average Tc-99m sestamibi uptake in the central infarct
region of patients with inferior infarcts scored as viable by
FDG PET was significantly lower (43 6 6%; n 5 15) than in
patients with anterior infarcts (65 6 14%, p , 0.002), but was
significantly higher than in patients with inferior infarction
scored as nonviable by FDG PET (32 6 5%; n 5 7; p , 0.002,
Fig. 2).
Prediction of viability by Tc-99m sestamibi data. As ante-
rior and inferior infarcts had significantly different mean
Tc-99m sestamibi uptake values in regions with an average
FDG uptake $50%, positive and negative predictive values
were calculated separately according to infarct location.
A threshold of 50% in patients with anterior infarcts yielded
the best positive (100% [7 of 7 patients]) and negative predic-
tive value (91% [10 of 11 patients]) for an average FDG uptake
of $50%. The diagnostic accuracy was 94% (17 of 18 patients).
In contrast, in patients with inferior infarcts a threshold of 35%
yielded the best positive (93% [14 of 15 patients]) and negative
predictive values (86% [6 of 7 patients]) for an average FDG
uptake of $50%. The diagnostic accuracy was 91% (20 of 22
patients).
Using infarct location adjusted, optimal Tc-99m sestamibi
thresholds (50% of maximal uptake for anterior infarcts and
35% of maximal uptake for inferior infarcts), the positive
predictive value was 95% (21 of 22 patients) and the negative
predictive value was 89% (16 of 18 patients) for an average
FDG uptake of $50% in the central infarct region in the total
group. The diagnostic accuracy was 93% (37 of 40 patients).
Tc-99m sestamibi uptake in the central infarct region of
patients with and without improvement of left ventricular func-
tion. Parameters of wall motion abnormality. Wall motion
abnormality in the central infarct region improved in 19
patients significantly by 1.1 6 0.78 SD (from 23.1 6 0.6 to
22.0 6 0.8, p , 0.0001), while in 12 patients wall motion
abnormality remained almost unchanged (22.9 6 0.45 SD to
22.8 6 0.8 SD, p 5 NS). Similarly, left ventricular ejection
fraction increased only in patients with significant improve-
ment of wall motion abnormality of the central infarct region
(from 50 6 13% to 58 6 13%, p , 0.01), while in patients
without significant improvement of wall motion abnormality of
the central infarct region, left ventricular ejection fraction
remained almost unchanged (from 57 6 8% to 54 6 7%, p 5
NS).
Table 1. Baseline Patient Characteristics





Anterior Infarct 18 (45%)
Inferior Infarct 22 (55%)




Extent of coronary artery disease
Single vessel disease 16 (40%)
Double vessel disease 6 (15%)
Triple vessel disease 18 (45%)
Wall motion abnormality of the central infarct region (SD) 22.9 6 0.5
Ejection fraction (%) 54 6 12
Data presented are mean 6 SD or number (%) of patients. CABG 5
coronary artery bypass graft surgery; CCS 5 Canadian Cardiovascular Society;
PTCA 5 percutaneous transluminal coronary angioplasty.
Figure 2. Average Tc-99m sestamibi uptake in the central infarct
regions defined as viable or nonviable by FDG PET in patients with
anterior and inferior infarcts.
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Average Tc-99m sestamibi uptake. The average Tc-99m
sestamibi uptake assessed before revascularization in the cen-
tral infarct region of patients with improved left ventricular
function (n 5 19) was 50 6 13% and was significantly higher
than in patients without improvement of function (37 6 12%;
n 5 12; p , 0.006). The average Tc-99m sestamibi uptake in
the central infarct region of patients with anterior infarcts and
improvement of left ventricular function (n 5 5) was signifi-
cantly higher (68 6 12%) than in patients without improve-
ment of function (40 6 14%; n 5 8; p , 0.02, Fig. 3). The
average Tc-99m sestamibi uptake in the central infarct region
of patients with inferior infarcts and improvement of left
ventricular function (n 5 14) was significantly lower (43 6 7%)
than in patients with anterior infarcts and improvement of
function (68 6 12%, p , 0.003), but was significantly higher
than in patients with inferior infarction and no improvement of
function (31 6 6%; n 5 4; p , 0.02; Fig. 3).
Prediction of improvement of wall motion abnormality
assessed by angiography from Tc-99m sestamibi data. For
patients with anterior infarcts an average Tc-99m sestamibi
uptake of $50% had the best positive (83% [5 of 6 patients])
and negative predictive value (100% [7 of 7 patients]) and a
diagnostic accuracy of 92% (12 of 13 patients) for improve-
ment of wall motion. For patients with inferior infarcts an
average Tc-99m sestamibi uptake of $35% had the best
positive (93% [13 of 14 patients]) and negative predictive value
(75% [3 of 4 patients]) and a diagnostic accuracy of 89% (16 of
18 patients) for improvement of wall motion abnormalities.
Using an infarct location adjusted optimal Tc-99m sestamibi
threshold ($50% for anterior infarcts, $35% for inferior
infarcts) for the total successfully revascularized group, the
positive predictive value was 90% (18 of 20 patients), the
negative predictive value was 91% (10 of 11 patients) and the
diagnostic accuracy was 90% (28 of 31 patients) for improve-
ment of left ventricular function.
Discussion
The data of this study indicate that rest Tc-99m sestamibi
SPECT can reliably predict myocardial viability as defined by
FDG PET or improvement of left ventricular function pro-
vided that Tc-99m sestamibi SPECT is carried out under
nitrate medication and that infarct location adjusted thres-
holds are applied.
Tc-99m sestamibi and myocardial viability. Tc-99m sesta-
mibi scintigraphy has been used to assess residual viability after
myocardial infarction over several years, but the results have
been controversial. Initially, Tc-99m sestamibi uptake has been
shown to underestimate the extent of viable myocardium in
comparison to FDG PET or rest Tl-201 scintigraphy (4–6).
Soufer et al. (4) also showed that Tc-99m sestamibi scintigra-
phy significantly underestimated the extent of viable myocar-
dium defined by FDG PET and improvement of left ventricu-
lar function. Interestingly, most of the Tc-99m sestamibi
nonviable/FDG viable segments (the mismatch segments) were
found in inferior infarct regions (22 regions) while in anterior
infarct regions only four regions showed a mismatch pattern.
This suggests that in some patients with inferior infarcts,
attenuation problems might account for the underestimation
of viability. Similarly, Sawada et al. (5) examined 20 patients
with Tc-99m sestamibi SPECT and FDG PET and showed that
in about 50% of segments with severely depressed Tc-99m
sestamibi uptake, a considerable FDG uptake could be found.
This is indicative of persistent viability.
Improved techniques to detect viability by Tc-99m sesta-
mibi. In contrast to these data, recent data indicate that rest
Tc-99m sestamibi scintigraphy can reliably detect residual
viability if late scintigraphy (11), scintigraphy under nitrate
medication (12,13) or quantitative analysis of Tc-99m sesta-
mibi uptake (7,8,11) were used.
Although it was initially believed that Tc-99m sestamibi
does not redistribute, recent data show that a considerable
redistribution in defects with initially severely reduced Tc-99m
sestamibi uptake may occur. Dilsizan et al. (11) examined this
effect in 18 patients with chronic myocardial infarction who
underwent Tl-201 SPECT and rest/stress Tc-99m sestamibi
SPECT and a delayed (4 h) Tc-99m sestamibi scan. The
delayed scan improved the concordance between rest Tl-201
and rest Tc-99m sestamibi scintigraphy from 71% to 82% with
regard to the detection of viability.
A further improvement of the detection of residual viability
after myocardial infarction by Tc-99m sestamibi SPECT has
been shown by the administration of nitrates before the
injection of Tc-99m sestamibi (13,18). Maurea et al. (13)
examined 31 patients after myocardial infarction with Tc-99m
sestamibi scintigraphy under baseline conditions and after oral
nitrates and with Tl-201 rest-redistribution scintigraphy. Eight
patients were also examined after revascularization. The ad-
ministration of nitrates improved the Tc-99m sestamibi uptake
in 54 segments with initially severely depressed Tc-99m sesta-
mibi uptake (from 42% to 60%, p , 0.001); all of these
segments were viable on rest-redistribution, Tl-201 scintigra-
phy. In the eight patients studied after revascularization, 87%
of the segments with reversible Tc-99m sestamibi defects
showed recovery, while 89% of the segments with irreversible
defects did not. Thus, nitrate administration seems to increase
blood flow and Tc-99m sestamibi uptake to severely ischemic
Figure 3. Average Tc-99m sestamibi uptake in the central infarct
regions defined as viable and nonviable by improvement of left
ventricular function in patients with anterior or inferior infarcts.
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but viable regions and improves detection of viable myocar-
dium.
Finally, the detection of viable myocardium after myocar-
dial infarction can be further improved by quantitative analysis
of Tc-99m sestamibi uptake (7,8,11,18). Undelson et al. (7)
examined 31 patients with coronary artery disease and left
ventricular dysfunction using rest-redistribution Tl-201 and
rest Tc-99m sestamibi scintigraphy, 18 of whom underwent
myocardial revascularization. Quantitative analysis of tracer
uptake showed a significant correlation (r 5 0.86) between
regional Tl-201 and Tc-99m sestamibi uptake. The average
tracer uptake was similar for both tracers (72% vs. 75%, p 5
NS) in patients with improvement of left ventricular function
assessed 20 days after revascularization by echocardiography.
Similarly, in regions without improvement of function, no
significant difference between both tracers was found (51% vs.
50%, p 5 NS). The authors concluded that rest Tc-99m
sestamibi scintigraphy using quantitative analysis was as accu-
rate as Tl-201 scintigraphy to detect viable myocardium and
predict improvement of left ventricular function after revascu-
larization.
Infarct location adjusted threshold for Tc-99m sestamibi
uptake. Based on these findings we combined the three above-
mentioned modalities (nitrate medication, delayed scan and
quantitative analysis) to optimize the predictive value of
Tc-99m sestamibi imaging for detection of residual viability. In
addition, we calculated infarct location adjusted thresholds for
the detection of residual viability as defined by PET, and
improvement of wall motion abnormality as the average Tc-
99m sestamibi uptake in viable inferior regions was signifi-
cantly lower than in anterior regions.
Our data confirm earlier reports in smaller patient popula-
tions and extend the knowledge about Tc-99m sestamibi
scintigraphy for detection of viability by demonstrating for the
first time that infarct location adjusted thresholds will further
improve the diagnostic accuracy of Tc-99m sestamibi scintig-
raphy. Although the attenuation of single photons by sur-
rounding tissue has been early identified as a potential limita-
tion in SPECT (19), this important problem has not yet
received much attention in the diagnosis of viability. Moreover,
the exact location of myocardial infarcts was not routinely
reported in studies analyzing the predictive value of Tl-201 or
Tc-99m sestamibi SPECT for assessment of viability, thus
making it impossible to draw any conclusions about the
average tracer uptake with respect to infarct location. Re-
cently, Maes et al. (9) compared the average Tc-99m sestamibi
uptake in patients with left anterior descending stenoses and
anterior wall motion abnormalities with the average FDG
uptake. They showed a linear relation between the histologi-
cally proven extent of necrosis and the regional Tc-99m
sestamibi uptake (r 5 0.78). In addition, a threshold of 50% of
maximal Tc-99m sestamibi uptake had the best predictive
value for improvement of left ventricular function in these
patients with anterior wall motion abnormality. These data are
similar to our observation showing that a threshold of $50%
for anterior infarct had the best positive and negative predic-
tive values. Unfortunately, no histological data exist for pa-
tients with inferior infarcts. However, our data indicate that in
these patients segments with evidence of viability (FDG uptake
$50% or improvement of wall motion abnormality) had a
significantly lower average Tc-99m sestamibi uptake (43%)
than in anterior regions (65%). This finding may explain why in
the report by Soufer et al. (4), using a single Tc-99m sestamibi
threshold of 50% of maximum Tc-99m sestamibi uptake most
of the segments which were nonviable by Tc-99m sestamibi but
viable by FDG PET were found in the inferior regions (22 of
39 segments). An infarct location adjusted threshold would
probably have improved these results.
Limitations. The matching of the RAO angiogram and the
scintigraphic images may be less than perfect. However, the
scintigraphic studies and the angiogram as its centerline anal-
ysis were compared side by side by a single observer, without
the knowledge of the functional outcome, thus minimizing any
potential bias. A second limitation is that we performed
Tc-99m sestamibi scintigraphy 2 h after injection of Tc-99m
sestamibi, for logistic reasons. A longer period between injec-
tion and scintigraphy may have further improved the predictive
value of Tc-99m sestamibi scintigraphy for the detection of
viable myocardium. As our study population comprised mainly
men with only modestly depressed left ventricular function, the
significance of our results for cardiac SPECT in women or
patients with severely depressed left ventricular function re-
mains to be determined. In the present study attenuation
correction was not used. The routine use of attenuation
correction may facilitate the interpretation of cardiac SPECT
studies in the future (20).
Clinical implications. Rest Tc-99m sestamibi scintigraphy
has the potential to assess reliably myocardial viability in
patients with Q wave myocardial infarction provided that late
scintigraphy after nitrate is performed and that infarct location
adjusted thresholds are applied. The broad availability and the
convenient logistics in preparing this tracer make Tc-99m
sestamibi a cost-effective alternative to the cyclotron-produced
FDG for routine assessment of residual viability.
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